News &amp; Updates

Transarterial infusion chemotherapy with microsphere embolization is an effective treatment option for gastroesophageal junction cancer with hepatic metastasis, a recent study has found.

Transarterial infusion chemotherapy, microsphere embolization effective for gastroesophageal cancer

Cognitive function: MEF2 confers resilience to neurodegeneration

06 Nov 2021 by

A study using RNA sequencing of human cortical tissue and animal models reveals the role of MEF2 transcription factors in promoting cognitive resilience (CgR).

Cognitive function: MEF2 confers resilience to neurodegeneration

Cycling: Greater risk of ICH vs other sports, helmets provide significant protection

06 Nov 2021 by

A multicentre study of hospitalized patients with sports- and recreational cycling–related traumatic brain injury (TBI) in Hong Kong finds cycling-related injuries carry greater risks of unfavourable outcomes and intracranial haemorrhage (ICH) vs other sports, with helmets providing significant protection against the latter.

Cycling: Greater risk of ICH vs other sports, helmets provide significant protection

First-cycle chemo modifications common among older adults with advanced cancer

Treatment modification at the first cycle is common among elderly adults with advanced cancer, a recent study has found. Factors contributing to such a need include increasing age, lower income, and functional impairment.

First-cycle chemo modifications common among older adults with advanced cancer

Nintedanib slows course of interstitial lung disease in Asians

Use of nintedanib in the treatment of interstitial lung disease (ILD) appears to delay its progression in Japanese patients, independent of the fibrotic pattern on high-resolution computed tomography (HRCT), as shown in a subgroup analysis of the phase III INBUILD trial.

Nintedanib slows course of interstitial lung disease in Asians

FFR-guided treatment fails to lower risk of death, CV events in multivessel CAD

A fractional flow reserve (FFR)-guided treatment strategy falls short of decreasing the risk of ischaemic cardiovascular (CV) events or death in patients with multivessel coronary artery disease (CAD) at 1-year follow-up, reveals a study.

FFR-guided treatment fails to lower risk of death, CV events in multivessel CAD

Erectile dysfunction in RA tied to lower risk of heart failure, myocardial infarction

The incidence of erectile dysfunction (ED) is not statistically higher in patients with rheumatoid arthritis (RA), a study has found. ED also does not increase the overall rate of cardiovascular events in RA, but it contributes to an increased risk of peripheral arterial disease (PAD) and a decreased risk of myocardial infarction (MI), heart failure (HF), and death.

Erectile dysfunction in RA tied to lower risk of heart failure, myocardial infarction

Chlormadinone prolongs active surveillance, maintains QoL in men with prostate cancer

Use of the oral antiandrogen chlormadinone at a low dose led to improvements in persistence rate of active surveillance (AS), PSA* and testosterone levels and prostate volume, and quality of life (QoL) in men with low-risk prostate cancer (PCa), the PROSAS study has shown.

Chlormadinone prolongs active surveillance, maintains QoL in men with prostate cancer

05 Nov 2021

TMVR outcomes in severe MR patients persist up to 2 years

Transcatheter mitral valve replacement (TMVR) in patients with severe symptomatic mitral regurgitation (MR) has sustained impact on severity of MR, reduction in heart failure hospitalization (HFH), and improvement in symptom through 2 years, a study has shown. Moreover, the first 3 months after the procedure show the highest all-cause mortality and need for HFH.

TMVR outcomes in severe MR patients persist up to 2 years

Can smartwatches predict depression?